【Caliway*】Company's new drug CBL-514 injection for reducing abdominal subcutaneous fat, Asia-Pacific Phase II clinical trial CBL-0206, has completed Taiwan TFDA IND application today.
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Caliway Biomedical (康霈) announced the completion of its Taiwan TFDA IND application for CBL-514 injection's Asia-Pacific Phase II clinical trial (CBL-0206), aimed at reducing abdominal subcutaneous fat. This marks a significant step towards bringing a new non-invasive fat reduction treatment to market.